Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

Sacks-Davis, Rachel; van Santen, Daniela K; Boyd, Anders; Young, Jim; Stewart, Ashleigh; Doyle, Joseph S; Rauch, Andri; Mugglin, Catrina; Klein, Marina; van der Valk, Marc; Smit, Colette; Jarrin, Inmaculada; Berenguer, Juan; Lacombe, Karine; Requena, Maria-Bernarda; Wittkop, Linda; Leleux, Olivier; Bonnet, Fabrice; Salmon, Dominique; Matthews, Gail V; Guy, Rebecca; Martin, Natasha K; Spelman, Tim; Prins, Maria; Stoove, Mark; Hellard, Margaret; Hellard, Margaret E; Sacks-Davis, Rachel; van Santen, Daniela K; Stewart, Ashleigh; Ke, Tianhui; Zhang, Yanqin; Stoove, Mark; Guy, Rebecca; Pedrana, Alisa; Asselin, Jason; Dawe, Joshua; Wilkinson, Anna; Boyd, Anders; Smit, Colette; van der Valk, Marc; Schinkel, Janke; Wittkop, Linda; Salmon, Dominique; Sogni, Philippe; Esterle, Laure; Gilbert, Camille; Merchadou, Laurence; Gillet, Stephanie; Khan, Coralie; Bonnet, Fabrice; Leleux, Olivier; Le Marec, Fabien; Perrier, Adelaide; Matthews, Gail; Shaw, Ineke; Martinello, Marianne; Applegate, Tanya; Carson, Joanne; Doyle, Joseph S; Harney, Brendan; Bryant, Melissa; Jarrin Vera, Inmaculada; Berenguer, Juan; Alejos, Belen; Lazarus, Jeffrey V; Moreno, Cristina; Izquierdo, Rebecca; Rava, Marta; Klein, Marina; Wang, Shouao; Lumia, Jessica; Pexos, Costa; Peiris, Hansi; Saeed, Sahar; Moodie, Erica; Young, Jim; Pick, Neora; Conway, Brian; Hull, Mark; Wong, Alex; Gill, John; Barrett, Lisa; Cohen, Jeff; Cox, Joseph; Cote, Pierre; Haider, Shariq; Rouleau, Danielle; Vachon, Marie-Louise; Rachlis, Anita; Sandre, Roger; Walmsley, Sharon; Sadr, Aida; Cooper, Curtis; Sanche, Steve; Rauch, Andri; Mugglin, Catrina; Salazar-Viscaya, Luisa; Kusejko, Katharina; Prins, Maria; Hage, Kris; Lacombe, Karine; Requena, Maria-Bernada; Girard, Pierre-Marie; Brucker, Matthieu; Vincensini, Jean-Paul

doi:10.1016/s2352-3018(23)00267-9

Cited by 8 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is supported by declines in HCV primary incidence among GBM with HIV internationally 3 including Australia. 4 Likewise, declines in reinfection incidence have also been reported in a number of countries, 5 including Australia. 6 …”

Section: Introductionmentioning

confidence: 92%

Annual hepatitis C testing and positive tests among gay and bisexual men in Australia from 2016 to 2022: a serial cross-sectional analysis of sentinel surveillance data

Harney,

Sacks-Davis,

Traeger

et al. 2024

Sex Transm Infect

Self Cite

View full text Add to dashboard Cite

ObjectiveGuidelines recommend annual hepatitis C virus (HCV) testing for gay and bisexual men (GBM) with HIV and GBM prescribed HIV pre-exposure prophylaxis (PrEP). However, there is a limited understanding of HCV testing among GBM. We aimed to examine trends in HCV testing and positivity from 2016 to 2022.MethodsUsing sentinel surveillance data, we examined the proportion of GBM with at least one test and the proportion with a positive test in each year for HCV antibody testing among GBM with no previous HCV positive test, HCV RNA testing among GBM with a positive antibody test but no previous positive RNA test (naïve RNA testing), and HCV RNA testing among people who had a previous RNA positive test and a subsequent negative test (RNA follow-up testing). Trends were examined using logistic regression from 2016 to 2019 and 2020 to 2022.ResultsAmong GBM with HIV, from 2016 to 2019 antibody testing was stable averaging 55% tested annually. Declines were observed for both naïve HCV RNA testing (75.4%–41.4%: p<0.001) and follow-up HCV RNA testing (70.1%–44.5%: p<0.001). Test positivity declined for HCV antibody tests (2.0%–1.3%: p=0.001), HCV RNA naïve tests (75.4%–41.4%: p<0.001) and HCV RNA follow-up tests (11.3%–3.3%: p=0.001). There were minimal or no significant trends from 2020 to 2022.Among GBM prescribed PrEP, antibody testing declined from 2016 to 2019 (79.4%–69.4%: p<0.001) and was stable from 2020 to 2022. Naïve and follow-up HCV RNA testing was stable with an average of 55% and 60% tested each year, respectively. From 2016–2019, the proportion positive from HCV RNA naïve tests declined (44.1%–27.5%: p<0.046) with no significant change thereafter. Positive follow-up HCV RNA tests fluctuated with no or one new positive test among this group in most years.ConclusionThe proportion of GBM with positive HCV tests has declined, however a substantial proportion are not tested annually. A renewed focus on HCV testing, and treatment where required, is warranted to achieve HCV elimination among GBM in Australia.

show abstract